Miopatía necrotizante autoinmune. Presentación de un caso clínico

  • Sabrina Plou Sanatorio Juncal S.A, Temperley, Buenos Aires, Argentina
  • María Elena Gaona Sanatorio Juncal S.A, Temperley, Buenos Aires, Argentina
  • Víctor Caputo Sanatorio Juncal S.A, Temperley, Buenos Aires, Argentina
Palabras clave: necrotizante, inmunosupresión plena, rituximab

Resumen

Las miopatías inflamatorias (MI) son un grupo heterogéneo de enfermedades musculares de rara ocurrencia, caracterizadas por inflamación de los distintos componentes del tejido muscular, ya sea de forma aislada o, más comúnmente, en el contexto de una afección sistémica. Las miopatías necrotizantes inmunomediadas (MNIM) constituyen un subtipo de miopatía inflamatoria caracterizada por debilidad muscular proximal, necrosis de miofibrillas con mínimo infiltrado celular inflamatorio en la biopsia muscular e infrecuente compromiso extramuscular asociado.

Biografía del autor/a

Sabrina Plou, Sanatorio Juncal S.A, Temperley, Buenos Aires, Argentina
Servicio de Reumatología
María Elena Gaona, Sanatorio Juncal S.A, Temperley, Buenos Aires, Argentina
Servicio de Reumatología
Víctor Caputo, Sanatorio Juncal S.A, Temperley, Buenos Aires, Argentina
Servicio de Reumatología

Citas

I. Pinal-Fernández L, Casal-Domínguez M, Mammen AL. Immunemediated necrotizing myopathy. Curr Rheumatol Rep 2018; 20(4): 21.

II. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuro-muscul Disord 2004; 14(5):337-45. (PubMed: 15099594).

III. Allenbach Y, Mammen AL, Stenzel W, Benveniste O. Immune-mediated necrotizing myopathies working G. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2017 Most recent classification criteria in IMNM. It includes consensus treatment recommendations for the different IMNM subsets. Neuromuscul Disord. 2018 Jan; 28(1):87-99.

IV. Senecal JL, Raynauld JP, Troyanov Y. A new classification of adult autoimmune myositis (editorial). Arthritis Rheumatol 2017; 69(5):878-84.

V. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62(9):2757-66.

VI. Pinal-Fernández I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015; 42(8):1448-54.

VII. Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken) 2015; 67(10):1416-25.

VIII. Pinal-Fernández I, Parks C, Werner JL, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 2017; 69(2):263-70.

IX. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139 (Pt 8):2131-5.

X. Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015; 10:61.

XI. Limaye V, Bundell C, Hollingsworth P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015; 52(2):196-203.

XII. Mastaglia FL. Inflammatory muscle diseases. Neurol India 2008 jul-sep; 56 (3):263.

XIII. Acosta I, Matamala JM, Jara P, et al. Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo. Rev Med Chile 2019; Vol 147 (3):342-355.

Publicado
2021-09-01
Cómo citar
1.
Plou S, Gaona ME, Caputo V. Miopatía necrotizante autoinmune. Presentación de un caso clínico. Rev. Argent. Reumatol. [Internet]. 1 de septiembre de 2021 [citado 6 de febrero de 2023];32(3):24 -28. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/490